BPH investee Cortical Dynamics confirms brain monitoring device compatible with Philips’ industry leading system
BPH Energy (ASX: BPH) investee company Cortical Dynamics has been successful in testing and providing documentation to meet the necessary pre-requisites of a license and co-operation agreement with Philips Electronics North America Corporation.
The achievement allows Cortical to claim its brain anaesthesia response monitor (BARM) as a compatible and supported device for Philips’ patient monitoring systems IntelliVue MP40-90 and MX400-850 using its IntelliBridge EC10 interface module or IntelliBridge EC10 integral interface board.
Philips confirmed today that Cortical can claim compatibility of the BARM-PEC with its IntelliVue systems and will include the device in its list of open interface supported medical devices.
Neurotechnology company Cortical has developed the BARM as a next generation personalised “depth of anaesthesia” monitoring device for use in operating rooms and intensive care units.
It is complemented by the proprietary CORDYAN (Cortical Dynamics Analytics) system which is a learning app focused on anaesthesiology.
Anaesthetic agents
BARM is being developed to better detect the effect of anaesthetic agents on brain activity under a general operation, aiding anaesthetists in keeping patients optimally sedated.
The Australian manufactured and designed, electroencephalographically-based (EEG-based), system is configured to efficiently image and display complex information related to the clinically-relevant state of the brain.
Once commercialised, the system will be offered on a stand-alone basis or integrated into leading brand operating room monitors as a “plug and play” option.
Cortical continues the FDA 510K filing process for BARM in the US, assisted by Washington-based technical advisor MCRA.
FDA approval is a necessary precursor for sales of BARM to commence in that part of the world.
Diversified company
BPH is a diversified company holding investments in resources and medical technologies.
The company holds a 36% interest in unlisted oil and gas explorer Advent Energy and is also commercialising biomedical innovations emerging from collaborative research by leading universities, medical institutes and hospitals across Australia.
BPH’s primary investment in medtech is Cortical Dynamics’ BARM device.
Cortical has completed its first human clinical trial using BARM, which aimed to evaluate the monitor’s ability to distinguish between two doses of commonly-used analgesic agent fentanyl.
It was also designed to assess the immunity of BARM to a range of mechanical and electrical artefacts known to complicate EEG measurement.
A total of 25 patients undergoing coronary artery graft bypass surgery were recruited into the trial.